JohanssonJOEgbergNAsplund-CarlsonAACarlsonLA: Nicotinic acid treatment shifts the fibrinolytic balance favourably and lowers plasma fibrinogen in hypertriglyceridemic menJ Cardiovasc Risk1997, 4:165–171.
2.
ThompsonSGKienastJPykeSDHaverkateFVan De LooJC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectorisN Engl J Med1995, 332:635–641.
3.
WildSHFortmannSPMarcovinaSM: A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participantsArterioscler Thromb1997, 17:239–245.
4.
MussoniLMannucciLSirtoriMCameraMMadernaPSironiL: Hypertryglyceridemia and regulation of fibrinolytic activityArterioscler Thromb1992, 12:19–27.
5.
BroijersenAErikssonMWimanBAngelinBHjerndahlP: Gemfibrozil treatment of combined hyperlipoproteinemia: No improvement on fibrinolysis despite marked reduction of plasma triglyceride levelsArterioscler Thromb1996, 16:511–516.
6.
IacovielloLAmoreCCurtisADTacconiMTGaetanoGCerlettiC: Modulation of fibrinolytic response to venous occlusion in humans by a combination of low-dose aspirin and n-3 polyunsaturated fatty acidsArterioscler Thromb1992, 12:1191–1197.
7.
SpannaglMDrummerCFroschlHSchackyCLandgraf-LeursMCLandgrafR: Plasmatic factors of haemostatis remain essentially unchanged except for PAI activity during n-3 fatty acid intake in type I diabetes mellitusBlood Coagul Fibrinolysis1991, 2:259–265.
8.
GrundySM: Small LDL, atherogenic dyslipidemia, and the metabolic syndromeCirculation1997, 95:1–4.
9.
O'KeefeJHJrConnRDLavieCJJrBatemanTM: The new paradigm for coronary artery disease: Altering risk factors, atherosclerotic plaques, and clinical prognosisMayo Clin Proc1996, 71:957–965.
10.
RosensonRS: Beyond low-density lipoprotein cholesterol: A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excessArch Intern Med1996, 156:1278–1284.
11.
LamarcheBTchernofAMoorjaniSCantinBDagenaisGRLupienPJ: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in menCirculation1997, 95:69–75.
12.
HamstenAWimanBde FaireUBlombackM: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarctionN Engl J Med1985, 313:1557–1563.
13.
JeppesenJHeinHOSuadicaniPGyntelbergF: Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart diseaseArterioscler Thromb1997, 17:1114–1120.
14.
O'KeefeJHJrNelsonJHarrisWS: Lifestyle change for coronary artery diseasePostgrad Med1996, 99:89–105.
Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease. The Scandinavian Simvastatin Survival Study (4S)Lancet1994, 344:1383–1389.
17.
IllingworthDRSteinEAMichelYBDujovasCAFrostPHKnoppRH: Comparative effects of lovastatin and niacin in primary hypercholesterolemia: A prospective trialArch Intern Med1994, 154:1586–1595.
18.
O'KeefeJHJrHarrisWSNelsonJWindsorSL: Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemiaAm J Cardiol1995, 76:480–484.
19.
MckenneyJMProctorJDHarrisSChinchillVM: A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patientsJAMA1994, 271:672–677.
20.
GargRMalinowRPettingerMHunninghakeDB: Treatment with niacin increases plasma homocysteine levels [abstract]Circulation1996, 94:1–457.
21.
GrahamIMDalyLERefsumHMRobinsonKBrattstromLEUelandPM: Plasma homocysteine as a risk factor for vascular diseaseJAMA1997, 277:1775–1781.
22.
GuptaADennisVGreenRJacobsenDWArheartKRobinsonK: High homocysteine concentration, a risk factor for atherosclerotic complications of end stage renal disease, may be normalized by high doses of folic acidAm J Cardiol1994, 29 (suppl A):43A.
23.
CannerPLBergeKGWengerNKStamlerJFriedmanLPrineasRJ: Fifteen year mortality in coronary drug project patients: Long-term benefit with niacinJ Am Coll Cardiol1986, 8:1245–1255.
24.
CarlsonLARosenhamerG: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acidActa Med Scand1988, 233:405–418.
25.
BrownAGAlbersJJFisherLDSchaeferSMLinJ-TKaplanC: Regression of coronary disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoproteinN Engl J Med1990, 323:1289–1298.
26.
ColquhounDMHicksBJGlasziouP: Comparative meta-analysis of 6 statin and 9 non-statin coronary regression trials. Evidence that cholesterol lowering is the key to outcomesCirculation1996, 94:1–579.
27.
MostazaJMSchulzIVegaGLGrundySM: Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemiaAm J Cardiol1997, 79:1298–1301.
28.
DavignonJRoedererGMontignyMHaydenMRTanMHConnellyPW: Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemiaAm J Cardiol1994, 73:339–345.
